Lawrence and Isabel Barnett Drug Development Program - ALS Association
Funds late-stage preclinical research to advance promising ALS therapies from lab studies toward clinical trials, supporting both novel and repurposed drug candidates.
This grant is no longer accepting proposals
ALS Association has archived this opportunity.
Funder: ALS Association
Due Dates (Anticipated): December 2025 (Letter of Intent) | March 2026 (Full proposal, by invitation) | March 2026 (Letter of Intent) | June 2026 (Full proposal, by invitation)
Funding Amounts: Up to $500,000 total over 2 years; indirect costs capped at 10% of direct costs.
Summary: Supports preclinical assessment of new or repurposed ALS therapies, bridging research from laboratory to industry drug development.
Key Information: Two-step process: Letter of Intent required; full proposals by invitation only.
Description
This program funds preclinical drug development for amyotrophic lateral sclerosis (ALS), focusing on projects ready to transition from laboratory research to industry drug development. The goal is to bridge the critical "valley of death" funding gap, supporting promising therapies that have a high probability of reaching clinical trials within three years. Both novel and repurposed therapeutics are eligible, and the program encourages synergistic collaborations between academic and industry investigators worldwide. Funding is intended for IND-enabling studies and other late-stage preclinical activities necessary for advancing a therapeutic candidate toward clinical testing.
